154 related articles for article (PubMed ID: 25346520)
1. Engineering toxin-resistant therapeutic stem cells to treat brain tumors.
Stuckey DW; Hingtgen SD; Karakas N; Rich BE; Shah K
Stem Cells; 2015 Feb; 33(2):589-600. PubMed ID: 25346520
[TBL] [Abstract][Full Text] [Related]
2. IL13 Fused
Uludağ D; Karakaş N
Anticancer Res; 2021 Jul; 41(7):3471-3480. PubMed ID: 34230142
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.
Candolfi M; Xiong W; Yagiz K; Liu C; Muhammad AK; Puntel M; Foulad D; Zadmehr A; Ahlzadeh GE; Kroeger KM; Tesarfreund M; Lee S; Debinski W; Sareen D; Svendsen CN; Rodriguez R; Lowenstein PR; Castro MG
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20021-6. PubMed ID: 21030678
[TBL] [Abstract][Full Text] [Related]
4. Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas.
Kauer TM; Figueiredo JL; Hingtgen S; Shah K
Nat Neurosci; 2011 Dec; 15(2):197-204. PubMed ID: 22197831
[TBL] [Abstract][Full Text] [Related]
5. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
6. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
Husain SR; Puri RK
J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.
Mintz A; Gibo DM; Madhankumar AB; Debinski W
J Neurooncol; 2003; 64(1-2):117-23. PubMed ID: 12952292
[TBL] [Abstract][Full Text] [Related]
10. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
11. Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine-rich loop of diphtheria toxin.
Chiron MF; Ogata M; FitzGerald DJ
Mol Microbiol; 1996 Nov; 22(4):769-78. PubMed ID: 8951823
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-brain tumor cytotoxins specific for cancer cells.
Debinski W; Gibo DM; Obiri NI; Kealiher A; Puri RK
Nat Biotechnol; 1998 May; 16(5):449-53. PubMed ID: 9592393
[TBL] [Abstract][Full Text] [Related]
15. Clinical studies with targeted toxins in malignant glioma.
Rainov NG; Söling A
Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
[TBL] [Abstract][Full Text] [Related]
16. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.
Kawakami K; Kawakami M; Liu Q; Puri RK
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):230-7. PubMed ID: 16111594
[TBL] [Abstract][Full Text] [Related]
18. Increasing stability and toxicity of Pseudomonas exotoxin by attaching an antiproteasic Peptide.
Méré J; Chopard C; Bonhoure A; Morlon-Guyot J; Beaumelle B
Biochemistry; 2011 Nov; 50(46):10052-60. PubMed ID: 22014283
[TBL] [Abstract][Full Text] [Related]
19. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
20. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
